234 citations
,
September 2004 in “Clinical cancer research”
In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.
This review discusses various skin diseases with endocrinological origins and reports no clinical results, highlighting the need for interdisciplinary understanding in diagnosis.
In this case report, a patient on low-dose sorafenib for hepatocellular carcinoma developed a rare and severe facial acneiform eruption without other skin side effects, which improved only minimally with topical treatment.